Recent Conferences
October 14, 2010
Fall Forum
July 8, 2010
Summer Forum
April 15, 2010
Spring Forum
October 14, 2009
Accelerating High-Value Healthcare
September 16, 2009
Next Steps Toward a Robust Comparative Effectiveness Research Enterprise
July 20, 2009
Establishing a National Health Insurance Exchange
June 11, 2009
Federal Strategies for Promoting Affordable Biologics: Follow-On Biologic Competition
April 29, 2009
Implementing Bundled Payments for Health Care Services
November 24, 2008
Medicare Delivery System Reform
October 2, 2008
Specialty Pharmaceuticals: Policy Solutions for Encouraging Access and Affordability
July 16, 2008
Managing Specialty Pharmaceuticals
June 4, 2008
"Road Testing" Electronic Medical Records
April 30, 2008
Innovation Workgroup
April 10, 2008
Payment and Delivery System Reform
November 29, 2007
Comparative Effectiveness Congressional Briefing
November 27, 2007
Overview of Cost Management Strategies
October 24, 2007
Coverage With Evidence Development
October 2, 2007
Value-Based Payment for Medical Technologies
September 18, 2007
Personalized Medicine Conference
July 25, 2007
Comparative Effectiveness: Stakeholder Perspectives
April 11, 2007
Post Marketing Surveillance
February 14, 2007
Comparative Effectiveness Research: Congressional Briefing
November 30, 2006
Comparative Effectiveness Forum
October 12, 2006
Coverage Policy in an Era of Personalized Medicine
July 13, 2006
Pharmaceutical Benefit Management
May 1, 2006
Methodology Standards
April 4, 2006
Technology Assessment
October 3, 2005
Promoting Appropriate Utilization
April 1, 2005
Evidence-Based Health Care System
July 16, 2004
Correcting Underuse in Health Care
April 30, 2008
Health Care Innovation in the 21st Century: Incentives for Greater Value in an Era of Constrained Resources
Innovation is a core concept of the American economy, driving a continual stream of products, processes, and services of higher quality and lower cost than those that they replace. Innovative medical technologies provide important economic and patient benefits but have also been a major driver of health spending. Purchasers often have difficulty quantifying the value of new medical technologies and incremental innovations may come with substantial price premiums. In contrast, innovation in health care service delivery has been sluggish, allowing innefficiencies and quality problems to persist. Regulatory barriers and market failure including moral hazard and information asymmetry hinder innovation that could improve quality and lower costs. The growing health care affordability crisis will put financial pressure on developers and providers of health care services. This workgroup meeting will focus on developing options for driving health care innovation that generates both commercial and societial valie in an era of contrained resources.
Presentations:
Kevin Schulman, MD, Director, Center for Clinical and Genetic Economics & Health Sector Management Program, Duke University
Pharmaceutical Industry Perspective
Newell McElwee, Pharm.D, Vice President, Pfizer
Donald W. Moran, President, The Moran Company
A Model for Nurturing Innovation Through Translational Research
Colleen M. Kigin, PPT, Chief of Staff, Center for Integration of Medicine and Innovative Technology






